MS-Docblog

The Multiple Sclerosis Doctor Explains: www.ms-docblog.de

No one can report on Multiple Sclerosis as expertly and comprehensively as someone who deals with it professionally every day. On www.ms-docblog.de, Prof. Dr. med. Mathias Mäurer, as an MS expert and physician, shares insights from his medical practice and experiences with his patients. The Multiple Sclerosis doctor is a member of the Medical Advisory Board of AMSEL (Action Multiple Sclerosis Patients, State Association of the German Multiple Sclerosis Society in Baden-Württemberg) e.V. and, as a neurologist, is familiar with the issues that are relevant to MS sufferers.

Multiple Sclerosis: Medicine, Research, and Therapy

www.ms-docblog.de aims to reach many people and provide comprehensive information from an expert’s perspective. The scope of the blog and experienced chief physician Prof. Dr. med. Mathias Mäurer is extensive: MS definition, causes, progression, diagnosis, symptoms, therapy, research, medicine, and daily life are the topics that the expert addresses in his posts. He regularly discusses current developments and reports from MS conferences and meetings.

Answering Questions and Reducing Uncertainty

The neurologist is frequently confronted with questions by patients that are also relevant to other MS sufferers. Through the blog, he can reach many people and share important information. This helps to eliminate doubts and uncertainties that can arise when surfing through the numerous sources on the Internet.

Reliable Information Expertly Weighted

Prof. Dr. med. Mathias Mäurer provides orientation within the abundance of digitally offered information on www.ms-docblog.de for those affected by MS, points out misinformation, and presents interpretable facts about Multiple Sclerosis in a comprehensible context.
Whether it’s Multiple Sclerosis or even incorrect spellings: Muliple Sklerose, Multiplen Sklerose, Multiples Sklerose, or simply MS – here on the MS-DocBlog or on AMSEL.de you will be informed about the disease MS.

Neutropenia – A Rare Side Effect of Anti-CD20 Antibodies

19. August 2026 Prof. Dr. med. Mathias Mäurer MS Therapy

The MS therapy with anti-CD20 antibodies (Ocrelizumab – Ocrevus®, Ofatumumab – Kesimpta®, Ublituximab – Briumvi® and off-lable Rituximab) usually proceeds smoothly and without side effects, especially in younger patients – the drugs are all quite

Study on Generic Fingolimod

5. August 2026 Prof. Dr. med. Mathias Mäurer Life with MS

For some time now, the patent protection for the multiple sclerosis (MS) drug Gilenya® (Fingolimod) has expired – the active ingredient Fingolimod can therefore now be marketed as a generic drug.

Teaserbild für ein Video über eine Neuzulassung eines Medikamentes gegen Multiple Sklerose. EMA lässt Tolebrutinib zu: Videotitel, weiße Tabletten, Videopfeil für Play

EMA approves Tolebrutinib

10. July 2026 Prof. Dr. med. Mathias Mäurer General

At the end of June, the European Medicines Agency (short: EMA) approved the Bruton’s tyrosine kinase inhibitor Tolebrutinib (amsel.de reported immediately). The BTKi is approved for the indication of secondary progressive multiple sclerosis without relapses

News from AAN 2026: MOGAD

18. May 2026 Prof. Dr. med. Mathias Mäurer MS Therapy

Another important study presented at this year’s AAN 2026 is the METEROID study. This is about the effect of Satralizumab in patients with MOGAD. MOGAD stands for Myelin Oligodendrocyte Glycoprotein Antibody Associated Disease. This is

News from AAN 2026: BTKi

6. May 2026 Prof. Dr. med. Mathias Mäurer General

At the end of April, the annual meeting of the American Academy of Neurology (AAN) took place in Chicago. I had the opportunity to attend the congress on site and therefore want to summarize some

Lithium for Mental Health?

19. April 2026 Prof. Dr. med. Mathias Mäurer Life with MS

Currently, social networks are probably being flooded with half-truths about lithium. – That’s the only way I can explain why I’ve been asked again and again recently by relatives of patients with Alzheimer’s disease about

Anreißerbild zu Video "Actrims 2026 - Bücher und Lesebrille vor blauem Hintergrund.

ACTRIMS 2026: Ublituximab, Vidofludimus Calcium & GA Depot

1. April 2026 Prof. Dr. med. Mathias Mäurer General

Ublituximab in children, Vidofludimus Calcium in progression, Glatirameracetat in PPMS? All three were a topic at the ACTRIMS Congress in February 2026. Prof. Mathias Mäurer talks about the three active substances in this video. And

News about Fenebrutinib

1. April 2026 Prof. Dr. med. Mathias Mäurer MS Therapy

BTKi are considered to be the beacon of hope in the MS community, as they are supposed to specifically target and slow down the creeping parts of MS. BTKi are very small molecules that go

New on Tolebrutinib

12. March 2026 Prof. Dr. med. Mathias Mäurer MS Therapy

Tolebrutinib belongs to the class of Bruton tyrosine kinase inhibitors. Recently, negative news weakened hope for the BTKi, particularly among people with progressive multiple sclerosis. Professor Mathias Mäurer summarizes new information on Tolebrutinib in the

zwei runde, weiße Tabletten vor weißem Hintergrund

New Year, new on BTKi: PERSEUS Study misses the primary endpoint

14. January 2026 Prof. Dr. med. Mathias Mäurer General

First of all, I would like to wish all readers of MS-DocBlog a happy and successful new year. – Stay healthy and hopeful, despite all adversities. Speaking of adversities – this brings us right back

News from MS-DocBlog

Neutropenia – A Rare Side Effect of Anti-CD20 Antibodies

Study on Generic Fingolimod

EMA approves Tolebrutinib

News from AAN 2026: MOGAD

News from AAN 2026: BTKi

The Multiple Sclerosis Doctor Explains: www.ms-docblog.de

Multiple Sclerosis: Medicine, Research, and Therapy

Answering Questions and Reducing Uncertainty

Reliable Information Expertly Weighted

Neutropenia – A Rare Side Effect of Anti-CD20 Antibodies

Study on Generic Fingolimod

EMA approves Tolebrutinib

News from AAN 2026: MOGAD

News from AAN 2026: BTKi

Lithium for Mental Health?

ACTRIMS 2026: Ublituximab, Vidofludimus Calcium & GA Depot

News about Fenebrutinib

New on Tolebrutinib

New Year, new on BTKi: PERSEUS Study misses the primary endpoint

Thank You!

Recent Posts

Archive

Categories

Links

Follow us

The Expert

The Topics

The Community

News from MS-DocBlog

The Multiple Sclerosis Doctor Explains: www.ms-docblog.de

Multiple Sclerosis: Medicine, Research, and Therapy

Answering Questions and Reducing Uncertainty

Reliable Information Expertly Weighted

Thank You!

Recent Posts

Archive

Categories

Tags

Links

Follow us

The Expert

The Topics

The Community